Developer docs
API playgroundTry for free, no card

Search company profiles

Nested Therapeutics

Full company profile

uuid0000swf

Namestring
Nested Therapeutics
Legal namestring
Nested Therapeutics Inc.
Websiteurl
nestedtx.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nested Therapeutics is a Cambridge, Massachusetts-based precision oncology company founded in 2021 to discover and develop therapeutics against previously undruggable cancer targets. The company's core technology is a proprietary structural and AI-based drug discovery platform that integrates genomics, computational biophysics, machine learning, and chemical biology to systematically identify mutations that create novel binding pockets — including those at protein complex interfaces or those driving conformational changes — across the approximately 10,000 recurrent cancer-associated mutations in the human genome, of which less than 1% currently have FDA-approved medicines.

The company operates two pipeline programs. The lead asset, NST-628, is a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that targets multiple components of the RAS/MAPK pathway and has demonstrated superiority over single-agent and vertical combinations in preclinical RAS/MAPK-driven models. NST-628 entered a global two-part Phase 1 study in MAPK-driven solid tumors following FDA IND clearance in March 2024, with initial Phase 1 data presented at AACR 2026 showing a 38% response rate and 85% disease control rate in heavily pretreated NRAS and BRAF Class II/III melanoma patients. The second program is a mutation-selective p53 pathway allosteric molecule that binds a novel cryptic pocket on a frequently mutated transcriptional regulator, currently at lead compound stage.

Nested Therapeutics is pre-revenue and intends to monetize through drug development and commercialization, likely via licensing/royalties and partnerships with established pharmaceutical companies. The company is venture-backed, having raised $125 million in total financing anchored by Versant Ventures and Goldman Sachs Asset Management. The customer base consists of cancer patients with MAPK-driven solid tumors enrolled in clinical trials at global academic medical centers; the company employs 11–50 staff and is led by CEO Darrin Miles (formerly of Genentech and Agios), with a scientific co-founder bench including Kevan Shokat (UCSF/HHMI), Arvin Dar (MSKCC), and Klaus Hoeflich.

Short descriptiontext

Cambridge-based precision oncology company developing therapeutics against previously undruggable cancer targets using a proprietary structural and AI-based discovery platform. Lead program NST-628, a brain-penetrant pan-RAF/MEK molecular glue, is in Phase 1 trials for MAPK-driven solid tumors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
precision oncology therapeutics, cancer drug discovery, molecular glue drugs, RAS MAPK inhibitors, structural biology platform
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Precision Oncology Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Pre-revenue biopharmaceutical company developing precision oncology medicines. The company is advancing pipeline programs through clinical trials with plans for eventual commercialization of NST-628 and other pipeline candidates.

nestedtx.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Nested Therapeutics is a clinical-stage precision oncology company that uses a proprietary structural and AI-based drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology to identify previously undruggable cancer driver mutations and novel binding pockets. It is advancing a pipeline led by NST-628, a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue currently in a global Phase 1 study in MAPK-driven solid tumors, alongside a mutation-selective p53 pathway program in discovery.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 38% response rate and 85% disease control rate in heavily pretreated NRAS and BRAF Class II/III melanoma patients
+1 more record
Product overview1 text field

Nested Therapeutics is a precision oncology company with two pipeline programs. The lead program is NST-628, a non-degrading and fully brain-penetrant pan-RAF/MEK molecular glue targeting the RAS/MAPK pathway, currently in Phase 1 clinical trials. The second program is a mutation-selective p53 pathway program with an allosteric molecule targeting a transcriptional regulator. The company employs a proprietary structural and AI-based platform leveraging genomics, computational biophysics, machine learning, and chemical biology to discover new driver mutations and binding pockets in cancer targets.

Product and service2 records
1NST-628
CategoryClinical-Stage Precision Oncology Therapeutic
Description

A non-degrading and fully brain-penetrant pan-RAF/MEK molecular glue that targets multiple critical components in the RAS/MAPK pathway. It is being evaluated in a global two-part Phase 1 study in patients with MAPK-driven solid tumors and is intended for patients with NRAS-mutant melanoma, BRAF Class II/III melanoma, KRAS-mutant ovarian and cervical cancers, high-grade astrocytoma, and other RAS/MAPK-driven cancers.

2P53 Pathway Program
CategoryDiscovery-Stage Precision Oncology Therapeutic
Description

A mutation-selective program targeting the p53 pathway with an allosteric molecule targeting a transcriptional regulator frequently mutated in cancer. A lead compound with selective target binding to a novel cryptic pocket has been identified.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotechnology company developing precision oncology therapies with a focus on synthetic lethality and target discovery. Comparable as a platform-based precision oncology company at similar development stage.

TypeDirect peer
Description

Clinical-stage precision oncology company developing a portfolio of RAS/MAPK-targeted therapies including pan-RAF and MEK inhibitors. Direct competitor to Nested in the RAS/MAPK pathway with substantially more capital and pipeline depth.

TypeDirect peer
Description

Precision oncology company developing small molecule activators of p53, directly relevant to Nested's second pipeline program targeting the p53 pathway. Highly comparable target and approach.

TypeBroad incumbent
Description

Clinical-stage biotechnology company pioneering targeted protein degradation using PROTAC and molecular glue platforms. Comparable in therapeutic modality (molecular glues) and in oncology focus, though broader in target scope.

TypeDirect peer
Description

Precision oncology company leveraging a proprietary platform to discover and develop small molecule kinase inhibitors against both wild-type and mutant forms of cancer targets. Comparable platform-driven approach to nested cryptic-pocket discovery.

TypeDirect peer
Description

Clinical-stage precision oncology company building a pipeline of RAS/MAPK-targeted therapies. Direct competitor to Nested with multiple programs at various stages of development and similar MAPK-pathway focus.

TypeBroad incumbent
Description

Clinical-stage biopharmaceutical company developing targeted oncology therapies with several approved and clinical-stage assets. Comparable as a precision oncology company with similar MAPK-pathway interest (MEK inhibitors).

TypeDirect peer
Description

Developed targeted oncology drugs including KRAZATI (adagrasib), a KRAS G12C inhibitor, and other RAS-pathway agents. Direct overlap with Nested's RAS/MAPK focus; acquired by BMS in 2024 for ~$4.8B.

TypeEmerging player
Description

Clinical-stage precision oncology company using its proprietary gene regulation platform to discover and develop therapies targeting chromatin biology. Comparable as a platform-based precision oncology company targeting previously undruggable cancer biology.

TypeDirect peer
Description

Precision oncology company developing mutation-selective therapies against high-value cancer targets using a similar AI-enabled discovery approach. Highly comparable in strategy and stage to Nested's platform and p53 program.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nested Therapeutics

Precision Oncology Therapeuticsnestedtx.com

Cambridge-based precision oncology company developing therapeutics against previously undruggable cancer targets using a proprietary structural and AI-based discovery platform. Lead program NST-628, a brain-penetrant pan-RAF/MEK molecular glue, is in Phase 1 trials for MAPK-driven solid tumors.

What Nested Therapeutics does

Nested Therapeutics is a Cambridge, Massachusetts-based precision oncology company founded in 2021 to discover and develop therapeutics against previously undruggable cancer targets. The company's core technology is a proprietary structural and AI-based drug discovery platform that integrates genomics, computational biophysics, machine learning, and chemical biology to systematically identify mutations that create novel binding pockets — including those at protein complex interfaces or those driving conformational changes — across the approximately 10,000 recurrent cancer-associated mutations in the human genome, of which less than 1% currently have FDA-approved medicines.

The company operates two pipeline programs. The lead asset, NST-628, is a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue that targets multiple components of the RAS/MAPK pathway and has demonstrated superiority over single-agent and vertical combinations in preclinical RAS/MAPK-driven models. NST-628 entered a global two-part Phase 1 study in MAPK-driven solid tumors following FDA IND clearance in March 2024, with initial Phase 1 data presented at AACR 2026 showing a 38% response rate and 85% disease control rate in heavily pretreated NRAS and BRAF Class II/III melanoma patients. The second program is a mutation-selective p53 pathway allosteric molecule that binds a novel cryptic pocket on a frequently mutated transcriptional regulator, currently at lead compound stage.

Nested Therapeutics is pre-revenue and intends to monetize through drug development and commercialization, likely via licensing/royalties and partnerships with established pharmaceutical companies. The company is venture-backed, having raised $125 million in total financing anchored by Versant Ventures and Goldman Sachs Asset Management. The customer base consists of cancer patients with MAPK-driven solid tumors enrolled in clinical trials at global academic medical centers; the company employs 11–50 staff and is led by CEO Darrin Miles (formerly of Genentech and Agios), with a scientific co-founder bench including Kevan Shokat (UCSF/HHMI), Arvin Dar (MSKCC), and Klaus Hoeflich.

Nested Therapeutics firmographics

Firmographics
Name
Nested Therapeutics
Legal name
Nested Therapeutics Inc.
Website
https://nestedtx.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Cambridge-based precision oncology company developing therapeutics against previously undruggable cancer targets using a proprietary structural and AI-based discovery platform. Lead program NST-628, a brain-penetrant pan-RAF/MEK molecular glue, is in Phase 1 trials for MAPK-driven solid tumors.
Ownership category
akta.pro rank

Nested Therapeutics industry classification

Industry
Product category
Precision Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Precision oncology therapeutics
  • Cancer drug discovery
  • Molecular glue drugs
  • RAS MAPK inhibitors
  • Structural biology platform

Where Nested Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nested Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biopharmaceutical company developing precision oncology medicines. The company is advancing pipeline programs through clinical trials with plans for eventual commercialization of NST-628 and other pipeline candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Nested Therapeutics product offering

Product offering

Core offering

Nested Therapeutics is a clinical-stage precision oncology company that uses a proprietary structural and AI-based drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology to identify previously undruggable cancer driver mutations and novel binding pockets. It is advancing a pipeline led by NST-628, a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue currently in a global Phase 1 study in MAPK-driven solid tumors, alongside a mutation-selective p53 pathway program in discovery.

Product overview

Nested Therapeutics is a precision oncology company with two pipeline programs. The lead program is NST-628, a non-degrading and fully brain-penetrant pan-RAF/MEK molecular glue targeting the RAS/MAPK pathway, currently in Phase 1 clinical trials. The second program is a mutation-selective p53 pathway program with an allosteric molecule targeting a transcriptional regulator. The company employs a proprietary structural and AI-based platform leveraging genomics, computational biophysics, machine learning, and chemical biology to discover new driver mutations and binding pockets in cancer targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • NST-628 A non-degrading and fully brain-penetrant pan-RAF/MEK molecular glue that targets multiple critical components in the RAS/MAPK pathway. It is being evaluated in a global two-part Phase 1 study in patients with MAPK-driven solid tumors and is intended for patients with NRAS-mutant melanoma, BRAF Class II/III melanoma, KRAS-mutant ovarian and cervical cancers, high-grade astrocytoma, and other RAS/MAPK-driven cancers.
  • P53 Pathway Program A mutation-selective program targeting the p53 pathway with an allosteric molecule targeting a transcriptional regulator frequently mutated in cancer. A lead compound with selective target binding to a novel cryptic pocket has been identified.

Quantifiable outcome

  • 38% response rate and 85% disease control rate in heavily pretreated NRAS and BRAF Class II/III melanoma patients
  • +1 more outcomes

Companies that use Nested Therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Nested Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Nested Therapeutics partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Nested Therapeutics competitors and assessment

Company assessment

Direct peers

  • Tango Therapeutics: Clinical-stage biotechnology company developing precision oncology therapies with a focus on synthetic lethality and target discovery. Comparable as a platform-based precision oncology company at similar development stage.
  • Revolution Medicines: Clinical-stage precision oncology company developing a portfolio of RAS/MAPK-targeted therapies including pan-RAF and MEK inhibitors. Direct competitor to Nested in the RAS/MAPK pathway with substantially more capital and pipeline depth.
  • PMV Pharmaceuticals: Precision oncology company developing small molecule activators of p53, directly relevant to Nested's second pipeline program targeting the p53 pathway. Highly comparable target and approach.
  • Black Diamond Therapeutics: Precision oncology company leveraging a proprietary platform to discover and develop small molecule kinase inhibitors against both wild-type and mutant forms of cancer targets. Comparable platform-driven approach to nested cryptic-pocket discovery.
  • Erasca: Clinical-stage precision oncology company building a pipeline of RAS/MAPK-targeted therapies. Direct competitor to Nested with multiple programs at various stages of development and similar MAPK-pathway focus.
  • Mirati Therapeutics (acquired by Bristol-Myers Squibb): Developed targeted oncology drugs including KRAZATI (adagrasib), a KRAS G12C inhibitor, and other RAS-pathway agents. Direct overlap with Nested's RAS/MAPK focus; acquired by BMS in 2024 for ~$4.8B.
  • Scorpion Therapeutics: Precision oncology company developing mutation-selective therapies against high-value cancer targets using a similar AI-enabled discovery approach. Highly comparable in strategy and stage to Nested's platform and p53 program.

Broad incumbents

  • Arvinas: Clinical-stage biotechnology company pioneering targeted protein degradation using PROTAC and molecular glue platforms. Comparable in therapeutic modality (molecular glues) and in oncology focus, though broader in target scope.
  • SpringWorks Therapeutics: Clinical-stage biopharmaceutical company developing targeted oncology therapies with several approved and clinical-stage assets. Comparable as a precision oncology company with similar MAPK-pathway interest (MEK inhibitors).

Emerging players

  • Foghorn Therapeutics: Clinical-stage precision oncology company using its proprietary gene regulation platform to discover and develop therapies targeting chromatin biology. Comparable as a platform-based precision oncology company targeting previously undruggable cancer biology.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Nested Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nested Therapeutics leadership team

Management profile

Number of profiles

Profiles21 records

Nested Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nested Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nested Therapeutics

What does Nested Therapeutics do?

Nested Therapeutics is a clinical-stage precision oncology company that uses a proprietary structural and AI-based drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology to identify previously undruggable cancer driver mutations and novel binding pockets. It is advancing a pipeline led by NST-628, a non-degrading, fully brain-penetrant pan-RAF/MEK molecular glue currently in a global Phase 1 study in MAPK-driven solid tumors, alongside a mutation-selective p53 pathway program in discovery.

Is Nested Therapeutics a public or private company?

Nested Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nested Therapeutics founded?

Nested Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Nested Therapeutics based?

Nested Therapeutics is headquartered in Cambridge, United States, in the North America region.

How does Nested Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Nested Therapeutics's main competitors?

Direct peers on record are Tango Therapeutics, Revolution Medicines, PMV Pharmaceuticals, Black Diamond Therapeutics, Erasca, Mirati Therapeutics (acquired by Bristol-Myers Squibb) and Scorpion Therapeutics. Broad incumbents are Arvinas and SpringWorks Therapeutics. Foghorn Therapeutics is listed as an emerging player.

Does Nested Therapeutics have an API?

No public API is recorded for Nested Therapeutics.

What industry is Nested Therapeutics in?

Nested Therapeutics's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AijournNested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026Nested Therapeutics reported initial clinical results from its Phase 1 study of NST-628, a brain-penetrant pan-RAF/MEK molecular glue, showing a 38% response rate and 85% disease control rate in heavily pretreated NRAS and BRAF Class II/III melanoma patients at the recommended dose. The data was presented at the AACR Annual Meeting 2026 and demonstrated anti-tumor activity across multiple RAS/MAPK-driven tumors, including early evidence of central nervous system activity. The company plans to continue enrollment in the Phase 1 expansion cohort and evaluate NST-628 in additional malignant and non-malignant MAPK-driven diseases and combination settings.PR NewswireNested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026Nested Therapeutics reported initial Phase 1 clinical results for NST-628, a brain-penetrant pan-RAF/MEK molecular glue, showing a 38% response rate and 85% disease control rate at the recommended dose in heavily pretreated NRAS and BRAF Class II/III melanoma patients who have exhausted standard treatment options. The drug demonstrated anti-tumor activity across multiple RAS/MAPK-driven tumors including KRAS-mutant ovarian and cervical cancers, with early evidence of CNS activity including 70% tumor shrinkage in a high-grade astrocytoma patient. Nested Therapeutics plans to continue enrollment in the Phase 1 expansion cohort and evaluate NST-628 in additional malignant and non-malignant MAPK-driven diseases and combination settings.PR NewswireInductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested TherapeuticsInductive Bio published a study on its collaboration with Nested Therapeutics, combining ADMET foundation models with computational potency predictions. The approach reduced synthesized compounds and accelerated lead optimization. The companies plan to continue supporting partners in drug discovery.PR NewswireNested Therapeutics Announces Oral Presentation of Preclinical Data for NST-628, a Novel, Fully Brain-Penetrant, Pan-RAF/MEK Molecular Glue, at the 2024 AACR Annual MeetingNested Therapeutics presented preclinical data for its lead program NST-628 at the 2024 AACR Annual Meeting, with concurrent publication in Cancer Discovery, demonstrating the drug's differentiated mechanism and preclinical activity across KRAS-, NRAS-, and BRAF-driven tumors. The company announced that its Phase 1 open-label study is now open and enrolling patients with RAS-MAPK pathway-mutated advanced solid tumors, with dosing expected to begin imminently. NST-628 is a fully brain-penetrant, non-degrading molecular glue designed to target multiple nodes in the RAS-MAPK pathway and has the potential to address brain metastases and primary CNS malignancies with MAPK alterations.PR NewswireNested Therapeutics to Present Preclinical Data for NST-628, a Novel Pan-RAF/MEK Molecular Glue, in the New Drugs on the Horizon Series at 2024 AACR Annual MeetingNested Therapeutics announced that preclinical data for its lead program NST-628, a fully brain-penetrant non-degrading pan-RAF/MEK molecular glue targeting the RAS-MAPK pathway, will be presented at the 2024 AACR Annual Meeting in San Diego on April 8, 2024. The preclinical data demonstrated superior anti-tumor activity and tolerability compared to other MAPK-targeted compounds in RAS and central nervous system-implanted tumor models. The company is positioning NST-628 as a potential best-in-class treatment for RAS and RAF-driven cancers based on these findings.PR NewswireNested Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NST-628, a Novel Pan-RAF/MEK Molecular GlueNested Therapeutics announced FDA clearance of its investigational new drug application for NST-628, a novel pan-RAF/MEK molecular glue targeting the RAS-MAPK pathway in advanced solid tumors. The company plans to initiate dosing in a Phase 1 study in patients with RAS-MAPK pathway alterations in the first half of 2024, following activation of clinical trial sites. NST-628 is a fully brain-penetrant, non-degrading molecular glue designed to address resistance limitations of existing MAPK-targeted therapies.PR NewswireNested Therapeutics Presents First Preclinical Data for Lead Candidate, NST-628, a RAS/MAPK Pathway Inhibitor at 2023 AACR-NCI-EORTC ConferenceNested Therapeutics presented preclinical data for its lead candidate, NST-628, at the 2023 AACR-NCI-EORTC Conference in Boston, Massachusetts. The data showed that NST-628 demonstrated superior anti-cancer activity against multiple tumor types and has the potential for daily dosing due to its ability to effectively cross the blood-brain barrier. An IND filing is expected in the first half of 2024, paving the way for human clinical trials.PR NewswireNested Therapeutics to Present Preclinical Data for Novel, Potential Best-in-Class Inhibitor of the RAS/MAPK Pathway at 2023 AACR-NCI-EORTC ConferenceNested Therapeutics, a Cambridge-based biotechnology company, announced it will present preclinical data for its lead candidate NST-628 at the 2023 AACR-NCI-EORTC International Conference in Boston from October 11–15, 2023. The company will present three posters validating NST-628's mechanism of action as a novel non-degrading molecular glue targeting the RAS/MAPK pathway, including data suggesting potential superiority over other MAPK-targeted compounds. NST-628 is designed to address hard-to-treat cancers by inhibiting multiple nodes in the pathway, with one poster specifically highlighting its brain-penetrant properties in CNS tumor models.